AVTE News and Press, Aerovate Therapeutics Inc. From 08/15/22

Aerovate Therapeutics press release ( NASDAQ: AVTE ): Q2 GAAP EPS of -$0.49 misses by $0.03 . Cash, cash equivalents and short-term investments totaled $152.0 million as of June 30, 2022, compared to $167.4 million as of December 31, 2021. For further details see...

WALTHAM, Mass., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today announced financial results for t...

Gainers: Inotiv ( NOTV ) +18% . IO Biotech ( IOBT ) +16% . SOPHiA GENETICS ( SOPH ) +10% . Apyx Medical ( APYX ) +9% . Rhythm Pharmaceuticals ( RYTM ) +9% . Losers: Regulus Therapeutics ( RGLS ) -14% . Aerovate...

Baker Brothers’ 13F portfolio value decreased from $20.55B to $17.40B this quarter. Horizon Therapeutics was increased while decreasing Legend Biotech. The top three positions are Seagen, Incyte Corporation, and BeiGene, and they add up to almost 68% of the portfolio. ...

The following slide deck was published by Aerovate Therapeutics, Inc. in conjunction with this event. For further details see: Aerovate Therapeutics (AVTE) Investor Presentation - Slideshow

WALTHAM, Mass., June 02, 2022 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical-stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary diseases, today announced that Company management wi...

AV-101 is being developed to address cellular hyperproliferation and resistance to apoptosis in the pulmonary vasculature, which are key features of the pathophysiology of PAH PAH is an area of high unmet need, and currently approved therapies are limited by acting primarily thr...

Aerovate Therapeutics press release (NASDAQ:AVTE): Q1 GAAP EPS of -$0.45 misses by $0.17. Cash, cash equivalents and short-term investments of $161.1M. The company is reiterating strong financial position funding operations into the second half of 2025. The company expects to report topline d...

WALTHAM, Mass., May 16, 2022 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today announced financial results for th...

Gainers: Weidai (WEI) +68%. Manning & Napier (MN) +41%. Chicken Soup for the Soul Entertainment (CSSE) +28%. Hudson Capital (HUSN) +26%. Guardforce AI (GFAI) +19%. U.S. Xpress Enterprises (USX) +20%. Blackboxstocks (BLBX) +17%. Takung Art (TKAT) +17%. Borr Drilling (BORR) +17%. Clever Lea...